Company profile
Neobe Therapeutics Ltd
Error
Neobe Therapeutics Ltd is a UK company with status active founded in 2021 based in East of England.
Latest accounts
Financial period: 1 Feb 2024 to 31 Dec 2024
Company events
Reference milestones and recent Companies House filing stream events.
Accounts due
Accounts DueNext accounts due date
Confirmation statement due
Confirmation DueNext confirmation statement due date
Confirmation statement filed
ConfirmationLast confirmation statement made up date
Accounts filed
AccountsLast accounts made up date
Accounts With Accounts Type Total Exemption Full
Accounts AnalysedAA | Transaction MzQ0MDQzOTEzMGFkaXF6a2N4
Published 22 Oct 2024 07:05
Change Account Reference Date Company Current Shortened
Accounts AnalysedAA01 | Transaction MzQ0MDQ5OTQ1M2FkaXF6a2N4
Published 22 Oct 2024 02:51
Incorporated
InceptionCompany registered at Companies House
Public funding
Projects
Development and validation of a tumour inducible promoter platform for engineered live biotherapeutics
1 May 2024 to 31 Jan 2026
Neobe Therapeutics is an early-stage start up developing a synthetic biology platform to enable immunotherapy success in currently non responding cancer patients. Our platform is based on safe strains of tumour colonizing bacteria, which are engineered to be activated within solid tumours to release payloads that remove local barriers to immune infiltrati...
Pre-clinical development of a live biotherapeutic product engineered to remodel hyaluronic acid in solid tumours to enable checkpoint inhibitor efficacy
1 Dec 2023 to 30 Nov 2025
Neobe Therapeutics is an early-stage start up developing a synthetic biology platform to enable immunotherapy success in currently non responding cancer patients. Our platform is based on safe strains of tumour colonizing bacteria, which are engineered to be activated within solid tumours to release payloads which remove local barriers to immune infiltrat...
Engineering a new versican remodeling recombinant bacterial product to enable immunotherapy success in triple negative breast cancer
1 May 2022 to 30 Apr 2024
The cancer therapeutics field has been revolutionized by immunotherapy. The development of drugs that recruit the immune system to recognize and eliminate cancer cells has led to an extraordinary increase in patient survival, in some tumour types. However, only around 20% of patients with solid tumours are estimated to currently benefit from them. Multipl...